Bidepharm will continue to contribute to enlarge the domestic manufacturing capacity of drug molecular blocks after being successfully listed on SSE STAR Market.
Bidepharm (688073) was officially listed on the STAR Market of Shanghai Stock Exchange. It issued at the price of CNY 88 per share, and raised CNY 4.43 billion.
According to its prospectus, from 2019 to 2021, the company's revenue was CNY 249 million, CNY 390 million and CNY 606 million respectively. In the first half of 2022, Bide Pharm's revenue was CNY 369 million, up 37.41% year on year. From 2019 to 2021, the consolidated gross margin of the company was 59.66%, 54.38% and 49.46%, respectively, and the net profit after deducting non-profits was CNY 35.12 million, CNY 64.48 million and CNY 88.87 million, respectively.
Founded in 2007, Bidepharm is committed to becoming a global leading enterprise in the field of drug molecular block. It actively carries out the global layout, closely follows the pharmaceutical frontier R&D direction, quickly responds to customers' diversified needs for drug molecular block and scientific reagents, and help the global drug R&D institutions to accelerate the process of drug R&D and reduce the cost of drug R&D.
Pharmablock and Chemexpress are other Chinese companies that also specialises in developing drug molecular block.